Mechanisms of RhoGDI2 Mediated Lung Cancer Epithelial-Mesenchymal Transition Suppression

Huiyan Niu, Baogang Wu, Hongfang Jiang, Hui Li, Yi Zhang, Yang Peng, Ping He

Department of Geriatrics, Shengjing Hospital, China Medical University, Shenyang, China

Key Words
Lung cancer • RhoGDI2 • EMT • Metastasis

Abstract
Background: The aim of this study was to evaluate the function of RhoGDI2 in lung cancer epithelial-mesenchymal transition (EMT) process and to illustrate the underlying mechanisms that will lead to improvement of lung cancer treatment. Methods: The RhoGDI2 knock-down and overexpressing A549 cell lines were first constructed. The influence of RhoGDI2 on cytoskeleton in A549 cells was studied using two approaches: G-LISA-based Rac1 activity measurement and immunostaining-based F-actin distribution. The expression levels of key EMT genes were analyzed using real time quantitative polymerase chain reaction (RT-qPCR), western blot and immunostaining in untreated and RhoGDI2 knock-down or overexpressing A549 cells in both in vivo and in vitro experimental settings. Results: Our study showed that the activity of Rac1, a key gene that is crucial for the initiation and metastasis of human lung adenocarcinoma, causing the redistribution of F-actin with partial loss of cell-cell adhesions and stress fibers, was significantly suppressed by RhoGDI2. RhoGDI2 promoted the expression of EMT marker gene E-cadherin and repressed EMT promoting genes Slug, Snail, α-SMA in both A549 cells and lung and liver organs derived from the mouse models. Knocking-down RhoGDI2 induced abnormal morphology for lung organs. Conclusion: These findings indicate that RhoGDI2 repressed the activity of Rac1 and may be involved in the rearrangement of cytoskeleton in lung cancer cells. RhoGDI2 suppresses the metastasis of lung cancer mediated through EMT by regulating the expression of key genes such as E-cadherin, Slug, Snail and α-SMA in both in vivo and in vitro models.

Copyright © 2014 S. Karger AG, Basel
Introduction

Lung cancer is the number one cause of cancer mortality, killing more people than the total number of deaths caused by colon, pancreatic, breast and prostate cancers [1]. The prognosis for advanced lung cancer patients is very poor [2-4], which is often associated with epithelial-mesenchymal transition (EMT) mediated metastasis [5-8].

EMT was initially studied as a process during embryonic development in which epithelial cells emerge from their original niche and migrate to distal regions [6, 7, 9-12]. Recently more and more studies have suggested that EMT is a crucial process during cancer cells’ invasion and metastasis in which epithelial cells down-regulate epithelial adherens and tight junction proteins, lose apical-basal polarity and cell-cell contacts, and undergo remarkable remodeling of the cytoskeleton to facilitate cell motility and invasion [6, 9-11, 13, 14].

Rho GDP dissociation inhibitors (RhoGDIs), including three members, RhoGDI1, RhoGDI2 and RhoGDI3, are important regulators of Rho GTPases activity through protein-protein interaction [15-18]. One of the key functions of Rho GTPases is to remodel cytoskeleton components thus influence cell mobility. Therefore, it is not surprising that regulation of Rho family proteins can have profound impact on metastasis, a process that involves cancer cells migrating from one location to another and invading the destination tissue/organ [19]. RhoGDI2 is mainly expressed in hematopoietic cells and is differentially expressed in multiple cancers [20-22]. The roles of RhoGDI2 in regulating cancer cell growth and metastasis vary in different cancers. On the one hand, RhoGDI2 promotes the growth and invasion behavior for gastric, ovarian and breast cancers [23-26]. On the other hand, RhoGDI2 represses metastasis of bladder cancer and mouse lung cancer [19, 27-30]. However, the detailed mechanism by which RhoGDI2 regulates lung cancer EMT process is still elusive. Here, we report our work to demonstrate the roles played by RhoGDI2 in mediating the EMT process in lung cancer, through the use of an in vivo EMT model and in vitro protein chemistry.

Materials and Methods

Cell lines and antibodies

Lung cancer cell line A549 was purchased from Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences. The following antibodies were used: human anti-E-cadherin antibody (Santa Cruz Biotechnology), human anti-Slug antibody (Santa Cruz Biotechnology), human anti-Snail antibody (Santa Cruz Biotechnology), human anti-α-SMA antibody (Abcam), anti-F-actin (Abcam), and anti-β-actin (Santa Cruz Biotechnology).

Cell culture, gene knockdown and overexpression

A549 cells were cultured in RPMI-1640 medium containing 10% fetal bovine serum, 100 IU/ml penicillin and 100 μg/ml streptomycin. The cells were grown in a humidified incubator at 37 °C and under an atmosphere of 5% CO₂. Cells were grown on sterile tissue culture petri dishes and passaged once every 2 to 3 days [19, 31, 32].

Stable knockdown of RhoGDI2 was achieved by transfecting cells with shRNAs (5’ CCCCCGTCAATTATAAGCGCTCCATTCAAGAGATGGAGGCTTATAATTGAGCTTTTT 3’ and 5’ AAAGCTCAATTATAAGCGCTCCATTCAATTTGAATGGAGGCTTATAATTGAGCGGG 3’) -carrying lentivirus and by keeping cells cultured in selection media for 2 weeks. Cells with the most efficient knockdown were collected for subsequent experiments. Full-length RhoGDI2 was cloned into a pIREs2-EGF vector (Invitrogen). The pIREs2-EGFP-RhoGDI2 or the empty vector was transfected into cells using Lipofectamine 2000 transfection reagent (Invitrogen) according to the manufacturer’s recommendations.

Rac1 activity assay

The activity of Rac1 (GTP bound form) was quantified using G-LISA Rac1 activation assay Biochem Kit (Cytoskeleton) according to the manufacturer’s instructions. Briefly, a total of 180 μl protein extract...
was added to each corresponding well pre-coated with Rac-GTP-binding protein, with 36 μl Rac1 used as positive control. These were put on ice for 30 min followed by incubation with 20 μl of anti-Rac1 for 30 min. Subsequently, horseradish peroxidase (HRP)-conjugated secondary antibody (50 μl) was added to each well and incubation was continued for 45 min on ice. Subsequently, 50 μl HRP detection reagent was incubated for 20 min at room temperature. The reaction was stopped by adding 50 μl HRP stop solution and the absorbance was recorded at 490 nm (Biotek Instruments, Winsooki, VT). The activity of Rac1 was computed according to the manufacturer’s recommendation.

**RT-qPCR**

Total RNA was extracted from all samples using TRIZOL reagent (Invitrogen) according to manufacturer’s instructions, then reverse-transcribed using SuperScript First Strand cDNA System (Invitrogen) according to the manufacturer’s instructions. qPCR was performed using Exicycler 96 (BIONEER) following manufacturer’s advice. The sequences of the PCR primers are: E-cadherin-upstream (5’ ATGCCGCCATCGCTTACAC 3’), E-cadherin-downstream (5’ CGACGTTAGCCTGGTTCCTCA 3’), Slug-upstream (5’ AGCGAACTGGACACACATAC 3’), Slug-downstream (5’ GCCCCAAAGATGAGGAGTAT 3’), α-SMA-upstream (5’ TCCCTTGGAAAGATTACAGT 3’), α-SMA-downstream (5’ ATGAGTGCTGGTGGTGGTGTT 3’), β-actin-upstream (5’ CTAGTTGCGTGTTACACCTTTCTGTT 3’), β-actin-downstream (5’ CTGTACCTCCAGCTTTACAGTT 3’).

**Western blot**

Western blot was performed using standard technique. Briefly cells were lysed in RIPA buffer (20 mM Tris-HCl, pH 7.4, 20% glycerol, 0.5% NP-40, 1 mM MgCl₂, 0.5% NP-40, 1 mM EDTA, 1 mM EGTA, and aprotinin), and separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), transferred to polyvinylidene difluoride (PVDF) membrane, incubated for 2 h with antibodies in TBST containing 5% non-fat dried milk at room temperature. After incubation with appropriate horseradish peroxidase (HRP)-conjugated secondary antibodies, the signals were detected using ECL Western Blotting Detection Kit (BD Bioscience) after washing.

**Immunofluorescence**

Cells growing on the coverslips were washed briefly and fixed in 4% paraformaldehyde in PBS for 10 min on ice. After permeabilization in PBS containing 0.1% Triton X-100 on ice for 10 minutes, cells were washed using PBS for three times. After blocking in 5% milk for 30 min at 37 °C, anti-F-actin, and Cy3-conjugated anti rabbit IgG (Beyotime) antibodies were added with a dilution ratio as suggested by the manufacturer. Cells were then counterstained with DAPI (Biosharp). Fluorescent images were acquired using OLYMPUS IX51 confocal microscope after washing off the unbound secondary antibodies. The same procedure was used for cell staining by antibodies against E-cadherin, Slug, Snail and α-SMA.

**Mouse model for tumor metastasis**

Thirty healthy male mice with severe combined immunodeficiency (SCID) at the age 5 weeks post birth were selected. Each one of them weighted ~20 g. These mice were randomly assigned to 5 groups and each group was injected with untreated A549 cells, control knock-down A549 cells, RhoGDI2 knock-down A549 cells, control overexpression A549 cells and RhoGDI2 overexpressing A549 cells at a density of 2 × 10⁵ /200 μl, respectively. After 8 weeks, the lung and liver organs of the animals were harvested.

**Immunohistochemistry**

Immunohistochemical staining was performed on paraffin-embedded lung and liver organ specimens. Slides were routinely deparaffinized and hydrated. Subsequently, the sections were incubated in hematoxylin (Solarbio) for 5 min. After normal washing and soaking, the sections were counterstained with eosin for 3–5 min. After dehydration, clarification and sealing processes, the slides were imaged under DP73 (OLYMPUS).

**Statistical analysis**

Student’s t-test was used for all statistical analyses for experimental results. All statistical calculations were performed using R software. A p-value <0.05 was considered statistically significant.
Niu et al.: RhoGDI2 Suppresses EMT in Lung Cancer

Cellular Physiology and Biochemistry

Results

RhoGDI2 rearranges cytoskeleton

We first checked whether RhoGDI2 would affect the cytoskeleton of A549 cells. Rac1 is an important GTPase in regulating cytoskeleton organization, cell adhesion and transcriptional activation [33, 34]. Silencing Rac1 reduced the migration and invasion of lung cancer which was accompanied by concomitant cytoskeleton rearrangements [35]. Knock-down RhoGDI2 significantly increased Rac1 activity in A549 cells, whereas overexpressing RhoGDI2 significantly decreased the activity of Rac1 (Fig. 1A), indicating RhoGDI2 may repress the function of Rac1. Further, F-actin filaments became scattered throughout the cytoplasm and stress fibers were lost in RhoGDI2 knock-down A549 cells compared with control cells (Fig. 1B). Taken together, these results suggested that RhoGDI2 represses Rac1 activity, which in turn disrupts the redistribution of cytoskeleton during EMT.

RhoGDI2 promotes the expression of E-cadherin and represses Slug, Snail and α-SMA

Down-regulation of E-cadherin, a repressor of metastasis, is considered as the hallmark of EMT in cancer [36-38]. Several transcription factors such as Slug, Snail, are normally considered repressors for E-cadherin [36, 39-41]. In A549 cells, the knockdown of RhoGDI2 significantly decreased the expression of E-cadherin, whereas overexpressing RhoGDI2 increased the expression of E-cadherin (Fig. 2A and Fig. 3A, B). Conversely, knocking down RhoGDI2 promoted the expression of Slug, Snail and α-SMA while overexpressing RhoGDI2 repressed their expression (Fig. 2B-D and Fig. 3A, B). In combination, these results indicated that RhoGDI2 may regulate the expression of key EMT genes to effect the EMT process in A549 cells.

The morphology of lung and liver tissues from in vivo EMT model

To check the influence of RhoGDI2 on the morphology of lung and liver tissues, we stained lung and liver organs with hematoxylin and eosin. As expected, lungs extracted from mice injected with RhoGDI2 knock-down A549 cells showed significantly increased level of tumorigenesis, and those from mice injected with RhoGDI2 overexpressing A549 cells exhibited similar phenotypes to those of the control mice (Fig. 4). However, liver organs harvested from mice injected with either RhoGDI2 knock-down or overexpressing A549 cells showed no visible morphological changes from those of the control mice (Fig. 4). Taken together, these results provided evidence that RhoGDI2 may suppresses tumorigenesis in lung cells.
RhoGDI2 exhibits similar regulatory roles in cancer development in vivo as it does in vitro

To investigate the in vivo mechanism underlying RhoGDI2 repression of lung cancer metastasis, we checked the expression levels of key genes involved in the epithelial-mesenchymal transition (EMT) process. Similar to the results obtained in vitro (Fig. 3A-B), RhoGDI2 promoted the expression of E-cadherin and repressed the expression of Slug, Snail and α-SMA in both lung and liver organs (Fig. 5A-B and Fig. 6A-B). These results suggested that RhoGDI2 may regulate the expression of key genes involved in the EMT process.

Discussion

Despite recent advances in tumor-treatment technologies, lung cancer is still a top killer in all tumor-related deaths. Tumor metastasis is one of the major causes for lung cancer related death. RhoGDI2 is encoded by the ARHGDIB gene and is differentially expressed in various tissues in human [42]. While there are clear links between the alteration of RhoGDI2 protein levels and disease progression and/or the metastasis status in several types of cancer, the role that RhoGDI2 played in regulating cancer cell growth and metastasis varied in different types of cancers. For example, RhoGDI2 suppresses invasion and metastasis in bladder cancer and mouse lung cancer [19, 27-29] and is a positive prognostic factor [42]. Moreover, RhoGDI2 is selectively down-regulated in Hodgkin lymphoma cells compared with non-Hodgkin lymphoma [43]. But for gastric, ovarian and breast cancers, RhoGDI2 promoted
their growth and invasion behavior [23-26]. Therefore it is necessary to explore the underlying mechanism to explain the variety of functions that RhoGDI2 plays in different cancers. In previous studies, we found that the expression of RhoGDI2 protein was lower in lung cancer tissues than in normal lung tissues, and that RhoGDI2 may interact with the PI3K/Akt pathway [19]. Based on our data, we took lung cancer as a model system to study the potential roles that RhoGDI2 play in lung cancer EMT process and to illuminate the underlying mechanisms.

As a molecular switch for the organization and dynamics of the actin cytoskeleton, Rac-1 was found to be bound...
and activated by RhoGDI2 in bladder cancer [44], whereas this interaction inactivates Rac-1 in breast and gastric cancer [23, 45]. Our results showed that RhoGDI2 repressed the activity of Rac1, which is evidenced by the redistribution of F-actin with partial loss of cell-cell adhesions and stress fibers, and possibly the rearrangement of cytoskeleton in A549 cells. This further strengthens the notion that RhoGDI2 may play opposite roles in regulating cancer metastasis depending on cell types and cellular environment.

Epithelial-mesenchymal transition (EMT) is considered a crucial process for initiating cancer metastasis [6, 9-11, 13, 14]. During tumor EMT, epithelial tumor cells detach from their origin, obtain fibroblastic characteristics and migrate to distal regions to start the invasion process. E-cadherin is a cell-cell adhesion glycoprotein. Its expression is crucial for establishing and maintaining epithelial tissue structure [46]. Down-regulation of E-cadherin decreases cell adhesion strength and promotes motility, hence it is considered the fundamental hallmark of EMT in cancer [5, 6, 36-38]. It is widely accepted that E-cadherin represses cell invasion and metastasis [5, 6, 37, 38], and its activity can be regulated by several transcription factors e.g., Slug and Snail especially in lung carcinoma [36, 39-41]. Down-regulation of E-cadherin is usually caused by the expression of transcription factors such as Slug, Snail, Zeb1, E47 [36]. To better elucidate the role of RhoGDI2 in metastasis and cancer cell invasion, the effect of RhoGDI2 overexpression or depletion on EMT was investigated. As expected, the expression of E-cadherin, the hallmark and repressor of EMT process, was promoted by RhoGDI2 overexpression in A549 cells lines as well as in the lung and liver organs segregated from tumor metastasis mouse models. Accordingly, the expression of Slug, Snail and α-SMA was repressed by RhoGDI2 in both A549 cell lines and in vivo model. Animal experiments showed that knock-down RhoGDI2 did promote the metastasis of lung cancer.
Though the changes in the expression levels of key genes like E-cadherin, Slug, Snail and α-SMA were similar in lung and liver organs derived from tumor metastasis model in response to altered the expression of RhoGDI2, the number of nodules formed and the morphological changes in lung and liver were different. This suggests that there may exist other factors that are also involved in RhoGDI2-mediated EMT process whose roles are organ-specific roles. Further experiments are needed to shed more light on this phenomenon and to identify the direct down-stream targets of RhoGDI2 signaling.

Our work suggested that RhoGDI2 suppressed lung cancer EMT process and metastasis in vitro and in vivo by molecular mark detection and organ morphology characterization. We also found that the roles RhoGDI2 played in lung cancer metastasis were partly through altering cytoskeleton and by regulating the expression of key EMT genes. Our work hinted the potential of RhoGDI2 to serve as a therapy target for advanced lung cancer.

**Disclosure Statement**

The authors declare no competing interests.

**Acknowledgments**

This work was supported by a grant from the National Natural Science Foundation of China (No.81201832) and Specialized Research, Fund for the Doctoral Program of Higher Education (No. 20122104110011).
References


